BTK and chronic graft versus host disease: Similarly, BTKi, which blocks BTK, an essential component of the B cell receptor pathway whose signaling is indispensable for B cell survival and activation, and which are approved for B cell malignancies and chronic GVHD,29 may provide an alternative strategy to suppress pathogenic B cell activity in TED.